Cell Therapy (CAR-T)
1 ticker uses this canonical theme
Unclustered (1)
| Ticker | Conf. | Primary theme | Sub-industry |
|---|---|---|---|
| GILD | medium | HIV Franchise and Antiviral Pipeline Gilead's core HIV franchise remains resilient, while antiviral pipeline shifts from COVID to HDV/Ebola; CAR-T growth offers upside. | — |
★ = primary thesis · click ticker for full detail · cluster grouping reflects the latest cluster snapshot.